Prevalences of diabetes and impaired glucose regulation in a Danish population: The Inter99 study

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2335-2340

  Glümer, Charlotte ^a,b   Jørgensen, Torben ^b   Borch Johnsen, Knut ^a  

^a STENO DIABETES CENTER   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; DENMARK; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PREVALENCE;

ADULT; AGE DISTRIBUTION; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION;

EID: 17644434640     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2335     Document Type: Article

References (33)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727, 2002
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
4. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23:1278-1283, 2000
5. Drivsholm T, Ibsen H, Schroll M, Davidsen M, Borch-Johnsen K: Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med 18:126-132, 2001
6. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ: Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: the Hoorn Study. Diabetes Care 18:1270-1273, 1995
7. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE: Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population: the Rotterdam Study. Am J Epidemiol 145:24-32, 1997
8. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD, Cox LJ, Day NE, Hales CN, Palmer CR, et al: Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med 12:30-35, 1995
9. Dunstan DW, Zimmet PZ, Welborn TA, de Court, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829-834, 2002
10. Heine RJ, Mooy JM: Impaired glucose tolerance and unidentified diabetes. Postgrad Med J 72:67-71, 1996
11. The DECODE study group, European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
12. Claudi T, Midthjell K, Holmen J, Fougner K, Kruger O, Wiseth R: Cardiovascular disease and risk factors in persons with type 2 diabetes diagnosed in a large population screening: the Nord-Trondelag Diabetes Study, Norway. J Intern Med 248:492-500, 2000
13. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1:1373-1376, 1980
14. Midthjell K, Kruger O, Holmen J, Tverdal A, Claudi T, Bjorndal A, Magnus P: Rapid changes in the prevalence obesity and known diabetes in an adult Norwegian population: the Nord-Trondelag Health Surveys: 1984-1986 and 1995-1997. Diabetes Care 22:1813-1820, 1999
15. Joørgensen T, Borch-Johnsen K, Thomsen T, Ibsen H: Inter99: a population-based intervention among persons at high risk for cardiovascular disease. Jap J Card Dis Prev 36 (Suppl. A):171-182, 2001
16. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation, Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999 (WHO/NCD/NCS/99.2)
17. Saltin B, Grimby G: Physiological analysis of middle-aged and old former athletes: comparison with still active athletes of the same ages. Circulation 38:1104-1115, 1968
18. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, Chapman & Hall, 1993
19. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
20. Palta M, Prineas RJ, Berman R, Hannan P: Comparison of self-reported and measured height and Weight. Am J Epidemiol 115:223-230, 1982
21. Rowland ML: Self-reported weight and height. Am J Clin Nutr 52:1125-1133, 1990
22. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317:371-575, 1998
23. Ovesen L, Juul S, Mabeck CE: Sygdomsmønsteret i Almen Praksis, Århus Amt. Århus, Denmark, Institute of General Practice, 1997, p. 5-21
24. Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E, Bozzetti AM, Boari L, Lazzari P, Gallus G: Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 38:306-313, 1995
25. Leiter LA, Ross SA, Barr A, Tildesley HD, Belanger A, Fontaine N, Lubin S: Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 24:1038-1043, 2001
26. Collins R, Armitage J, Parish S, Sleight P, Peto R: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
27. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup II analyses in the Cholesterol and Recurrent Events (CARE) trial: the Care Investigators. Circulation 98:2513-2519, 1998
28. Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C, Fisher M, Wolffenbuttel B, Bosch J, Richardson L, Pogue J, Halle JP: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
29. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S, Matthews D, Neil A, Mcelroy H, Kohner E, Fox C, Hadden D, Wright D: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
30. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G: The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6-S11, 2000
31. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
32. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects witih impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
33. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002